Inflarx N.V. (IFRX) closed at $1.18 on November 11, 2026, down 2.5% from the previous close, on volume of 569,631 shares (30-day average 923,970).
Data as of November 11, 2026.
InflaRx Publishes Phase 1 Data Showing Favorable Izicopan Profile
TipRanks (Fri, 6-Nov 4:28 PM ET)
Globe Newswire (Fri, 6-Nov 7:30 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
InflaRx Announces November Investor Events
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026
Globe Newswire (Thu, 22-Oct 12:00 PM ET)
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Globe Newswire (Fri, 2-Oct 7:30 AM ET)
Globe Newswire (Thu, 1-Oct 7:30 AM ET)
InflaRx to Host Virtual Capital Markets Day
Globe Newswire (Mon, 21-Sep 7:30 AM ET)
InflaRx Announces Participation in September Investor Conferences
Globe Newswire (Thu, 20-Aug 7:30 AM ET)
InflaRx Regains Nasdaq Compliance After 10-Day Bid Price Streak
Market Chameleon (Tue, 28-Apr 6:31 AM ET)
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Inflarx N.V. trades on the NASDAQ stock market under the symbol IFRX.
As of November 11, 2026, IFRX stock price declined to $1.18 with 569,631 million shares trading.
IFRX has a beta of 3.92, meaning it tends to be more sensitive to market movements. IFRX has a correlation of 0.27 to the broad based SPY ETF.
IFRX has a market cap of $173.81 million. This is considered a Micro Cap stock.
Last quarter Inflarx N.V. reported $0 in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-10,000 and exceeded earnings estimates by $.05.
In the last 3 years, IFRX traded as high as $2.95 and as low as $.71.
The top ETF exchange traded funds that IFRX belongs to (by Net Assets): GWX, QQQS.
IFRX has underperformed the market in the last year with a price return of -25.3% while the SPY ETF gained +12.6%. IFRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.8% and -28.9%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
IFRX support price is $1.13 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IFRX shares will trade within this expected range on the day.